Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

A group of cystic fibrosis patients could be denied access to a cutting-edge therapy after manufacturer Vertex refused to submit data to cost-effectiveness body NICE. The manufacturer's decision ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

over the next six months as part of the company's transition towards becoming a developer of therapies that edit genes within the body. December 4, 2024 CMS enters agreement with Vertex ...